Watchlist

Watchlist
Anthera Pharmaceuticals, Inc. (ANTH)
Anthera Pharmaceuticals, Inc. (ANTH)
Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space
I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph…
Anthera Fails Phase 3 Study, Time To Avoid
Recently, Anthera Pharmaceuticals ( ANTH ) reported results from its Phase 3 trial treating exocrine pancreatic insufficiency ((EPI)) due to cystic fibrosis. It noted that the Phase 3 study failed to meet the primary endpoint . This sent shares of Anthera trading lower for…
U.S. Biotech/Pharma Sector Daily Observations Letter: March 13, 2018
The inflation data released today was underwhelming (bullish for stocks). Today was a small pullback day for U.S. equities after the recent rally from February lows but new highs are likely. Anthera Pharmaceuticals ( ANTH ) is trading at a market cap of just $11.3 million after the failur…
3 Things In Biotech, March 13, 2018: Uncertainty Abounds!
Note: Subscribers to Avisol Capital Partners' Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biote…
Anthera Pharmaceuticals (ANTH) Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura - Slideshow
The following slide deck was published by Anthera Pharmaceuticals, Inc. in conjunction with this Read more …
Your Daily Pharma Scoop: Coherus Biosciences Surges, Savara's Aironite Flops, Biogen's SPINRAZA
Analysis of top Seeking Alpha coverage: Coherus Biosciences Today we will discuss Coherus Biosciences (CHRS), which surged last Friday after the company announced that it is set to resubmit its application for Neulasta biosimilar. The company also noted that it expects an approval for the…
Midday Gainers / Losers (3/12/2018)
Gainers: BXC +83% . RKDA +51% . MARA +31% . OCLR +27% . NETE +23% . UCBA +23% . CPAH +18% . IMMP +17% . JNP +17% . More news on: BlueLinx Holdings, Inc., Arcadia Biosciences, Marathon Patent Group, Inc., Stocks on the move, , Read more …
Premarket Losers as of 9:05 am (3/12/2018)
ANTH -84% on terminating development of Sollpura after failed late-stage study. More news on: Anthera Pharmaceuticals, Inc., Orexigen Therapeutics, Inc., Savara Inc., Stocks on the move, , Read more …
Anthera to terminate development of Sollpura after failed late-stage study
Nano cap Anthera Pharmaceuticals (NASDAQ: ANTH ) is set for an ugly day after announcing that lead candidate Sollpura failed to demonstrate non-inferiority to Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals' PANCREAZE (pancrelipase) in a Phase 3 study. More news on: Anthe…
Premarket analyst action - healthcare
Endocyte (NASDAQ: ECYT ) initiated with Outperform rating and $20 (150% upside) price target at Wells Fargo. Shares up 4% premarket on modest volume. More news on: Endocyte, Inc., Corcept Therapeutics Incorporated, Masimo Corporation, Healthcare stocks news, Stocks on the move,…
Anthera Pharmaceuticals, Inc. (ANTH)